AU2017300268B2 - Methods of treating dry eye syndrome - Google Patents

Methods of treating dry eye syndrome Download PDF

Info

Publication number
AU2017300268B2
AU2017300268B2 AU2017300268A AU2017300268A AU2017300268B2 AU 2017300268 B2 AU2017300268 B2 AU 2017300268B2 AU 2017300268 A AU2017300268 A AU 2017300268A AU 2017300268 A AU2017300268 A AU 2017300268A AU 2017300268 B2 AU2017300268 B2 AU 2017300268B2
Authority
AU
Australia
Prior art keywords
subject
tear film
composition
eye
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017300268A
Other languages
English (en)
Other versions
AU2017300268A1 (en
Inventor
Sin Wook Kang
Kyoungsun Kim
Won Suk Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegenTree LLC
Original Assignee
RegenTree LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegenTree LLC filed Critical RegenTree LLC
Publication of AU2017300268A1 publication Critical patent/AU2017300268A1/en
Application granted granted Critical
Publication of AU2017300268B2 publication Critical patent/AU2017300268B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2017300268A 2016-07-18 2017-07-17 Methods of treating dry eye syndrome Active AU2017300268B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363565P 2016-07-18 2016-07-18
US201662363592P 2016-07-18 2016-07-18
US62/363,592 2016-07-18
US62/363,565 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (2)

Publication Number Publication Date
AU2017300268A1 AU2017300268A1 (en) 2019-01-31
AU2017300268B2 true AU2017300268B2 (en) 2024-06-13

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017300268A Active AU2017300268B2 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Country Status (8)

Country Link
US (2) US10960051B2 (enExample)
EP (1) EP3484497A4 (enExample)
JP (1) JP6889771B2 (enExample)
KR (1) KR102488796B1 (enExample)
CN (1) CN109789182A (enExample)
AU (1) AU2017300268B2 (enExample)
CA (1) CA3031069A1 (enExample)
WO (1) WO2018017479A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012808A1 (en) 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
CN101195025A (zh) * 2001-03-15 2008-06-11 雷金纳克斯生物制药公司 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
CA2458883C (en) * 2001-08-29 2017-11-28 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
JP2008526986A (ja) * 2005-01-13 2008-07-24 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 神経変性疾患、筋変性疾患または神経筋変性疾患による組織の変敗、傷害または損傷の治療方法または予防の方法あるいは前記疾患によって悪影響を受ける組織の修復方法
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
KR20080033939A (ko) * 2005-06-17 2008-04-17 리지너크스 바이오 파마소티컬스, 인코포레이티드 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法

Also Published As

Publication number Publication date
US10960051B2 (en) 2021-03-30
US20190240294A1 (en) 2019-08-08
JP6889771B2 (ja) 2021-06-18
CN109789182A (zh) 2019-05-21
AU2017300268A1 (en) 2019-01-31
EP3484497A4 (en) 2020-01-01
JP2019525923A (ja) 2019-09-12
KR102488796B1 (ko) 2023-01-13
CA3031069A1 (en) 2018-01-25
KR20190031280A (ko) 2019-03-25
EP3484497A1 (en) 2019-05-22
WO2018017479A1 (en) 2018-01-25
US20210213103A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
US9585941B2 (en) Eye drop formulation
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
US20210213103A1 (en) Methods of treating dry eye syndrome
AU2006260184A1 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
WO2010107069A1 (ja) アミノ酸含有眼科用組成物
EP3338792B1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
Tu et al. Dry eye
HK40012612A (en) Methods of treating dry eye syndrome
TW202033213A (zh) 脂聯素擬肽調配物
CN119730839A (zh) 稳定的肽组合物及使用其治疗中/重度干眼相关的眼部症状的方法
WO2020128616A2 (en) Methods and compositions for controlling cell migration and proliferation
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)